The European Health and Digital Executive Agency (HaDEA) has selected a consortium comprising SK bioscience, IDT Biologika, and Vaxxas for a next-generation influenza vaccine initiative. This project aims to develop seasonal vaccines for the elderly and pandemic vaccines for the general population, utilizing cutting-edge technology to strengthen the European Commission’s health preparedness.
The project’s innovation stems from the synergy between SK bioscience’s proprietary cell culture technology and Vaxxas’ high-density microarray patch (HD-MAP) needle-free delivery system. Under this framework, IDT Biologika—acquired by SK bioscience in late 2024—is expected to serve as the primary manufacturing hub within Europe.
The initial research and Phase I clinical trials are backed by €12.9 million in EU funding, part of a broader €225 million commitment to enhance regional vaccine commercialization and supply. If successful, these patch-based vaccines are projected to significantly reduce influenza-related morbidity and mortality. Furthermore, the consortium plans to enter major global markets, including South Korea and the United States, targeting the high-value seasonal flu segment for older adults.